141819-91-2

Basic information

• Product Name: 2-(5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-4-YL)ETHANOL
• Synonyms: 2-(5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-4-YL)ETHANOL;5-methyl-2-[4-(trifluoromethyl)phenyl]-4-Oxazoleethanol;4-Oxazoleethanol, 5-methyl-2-[4-(trifluoromethyl)phenyl]-
• CAS NO: 141819-91-2
• Molecular Formula: C₁₃H₁₂F₃NO₂
• Molecular Weight: 271.2350896
• Mol File: 141819-91-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 362.673°C at 760 mmHg
• Flash Point: 173.139°C
• Appearance: /
• Density: 1.286g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.501
• CAS DataBase Reference: 2-(5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-4-YL)ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-4-YL)ETHANOL(141819-91-2)
• EPA Substance Registry System: 2-(5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOL-4-YL)ETHANOL(141819-91-2)

Safety Data

• Hazardous Substances Data: 141819-91-2(Hazardous Substances Data)

Usage

Chemical class

Oxazoles, which are five-membered rings containing one oxygen and one nitrogen atom.

Structure

2-(5-Methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethanol consists of an oxazole ring with a methyl group at the 5-position, a phenyl group at the 2-position, and a trifluoromethyl group attached to the phenyl group.

Derivative

It is an ethanol derivative, with an hydroxyl (-OH) group attached to the 4-position of the oxazole ring.

Functional groups

The compound contains a trifluoromethylphenyl group, which is a phenyl group with three fluorine atoms attached to the methyl group.

Pharmaceutical applications

The compound has potential pharmaceutical applications, particularly in the development of new drugs and medications, due to its unique chemical structure and properties.

Research uses

2-(5-Methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethanol may have uses in chemical and biological research, providing valuable insights into the behavior and interactions of its structure in various experimental settings.

InChI:InChI=1/C13H12F3NO2/c1-8-11(6-7-18)17-12(19-8)9-2-4-10(5-3-9)13(14,15)16/h2-5,18H,6-7H2,1H3

Upstream product

• 475481-00-6 [5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-acetic acid 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 1891-90-3 p-trifluoromethylbenzamide 
• 258346-49-5 2-[2-[4-trifluoromethylphenyl)-5-methyl-1,3-oxazol-4-yl]acetic acid methyl ester 

Downstream Products

• 141820-03-3 4-(2-(5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl)ethoxy)benzaldehyde 
• 1058703-16-4 2-(6-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-pyridin-3-ylmethyl)-tetrahydro-furan-2-carboxylic acid ethyl ester 
• 1189748-76-2 C₂₂H₁₆F₃NO₃S 
• 475481-01-7 4-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-naphthalene-1-carbaldehyde 
• 1027551-69-4 N-(4-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-benzyl)-hydroxylamine 
• 141820-10-2 4-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-benzaldehyde oxime 

Relevant articles and documents

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Oxazole derivatives

The present invention relates to novel oxazole compounds which act as PPARα and PPARγ agonists and are accordingly useful for the treatment of diseases modulated by PPARα and PPARγ such as diabetes.

New azolidinediones as inhibitors of protein tyrosine phosphatase lb with antihyperglycemic properties

Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be negative regulators of the insulin receptor. Inhibiton of PTPases may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compounds were Potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the molecule as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones 87 and 88 and the corresponding acetic acid analogues 119 and 120 were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 μM. Several compounds normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.